What's New
  Microimmune About Us Products What's New How to order Contact Us
Products
Diagnostic Kits
Mumps IgG
Mumps IgM
Measles IgG
Measles IgM
Rubella IgM
Immunofluoresence
Monoclonals
EIA Reagents
Services
Hybridomas
Conjugation
Antisera
Development
Consultancy

What's New

Microimmune Ltd is leading the way in improved diagnosis and surveillance of vaccine preventable diseases. The ability to use oral fluid samples as well as serum or plasma samples in Microimmune test has a number of advantages including safety of sample collection and compliance of patients to provide samples. Surveillance efforts are much improved because subjects are likely to provide oral fluid samples which are painless to collect.

Product News

The company has re-focused some of its efforts and has withdrawn some of the less successful product lines and has replaced it with new products including the Mumps IgM capture EIA for the diagnosis of acute mumps infection. Look out for the Mumps IgG capture EIA which will be launched early 2004.

Customers may notice changes to the product labelling and product information sheets as the company applies for CE registration of its products.

Microimmune sponsors HPA Annual Golf Day

Microimmune is pleased to announce that it is sponsoring the Health Protection Agency (HPA) Annual Golf Tournament being held as part of the HPA Annual Conference at Warwick University from the 13th-15th Spetmeber 2004. More details here

British Council Link Programme

Microimmune's enzyme immunoassay products have featured in a number of projects world wide, including a British Council Link Programme on "A sustainable model for the use of oral fluid techniques in measles vaccine control programme and research", a measles vaccine study in Kilifi, Kenya and in an European Union funded Enhanced Laboratory Surveillance of Measles (ELSM) Program

World Health Organisation evaluate the Microimmune measles IgM capture EIA

The World Health Organisation(WHO) has been evaluating the measles IgM capture EIA using oral fluid specimens for the diagnosis and surveillance of measles in developing countries. The results have indicated that the test has good sensitivity and specificity compared to serum based tests. This will enable WHO promote the implementation of safer alternatives to the use of blood for serological diagnosis of measles.